Pharmacogenetics of beta-blockers.
Beta-blockers are an important cardiovascular drug class, recommended as first-line treatment of numerous diseases such as heart failure, hypertension, and angina, as well as treatment after myocardial infarction. However, responses to a beta-blocker are variable among patients. Results of numerous studies now suggest that genetic polymorphisms may contribute to variability in responses to beta-blockers. This review summarizes the pharmacogenetic data for beta-blockers in patients with various diseases and discusses the potential implications of beta-blocker pharmacogenetics in clinical practice.
Shin
Jaekyu
J
College of Pharmacy, Center for Pharmacogenetics, University of Florida, Gainesville, Florida 32610-0486, USA.
Johnson
Julie A
JA
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects / Q000235:genetics; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000235:genetics; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D006339:Heart Rate / Q000187:drug effects / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D018342:Receptors, Adrenergic, beta-1 / Q000235:genetics
D000319:Adrenergic beta-Antagonists; D018342:Receptors, Adrenergic, beta-1; D019389:Cytochrome P-450 CYP2D6